Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.
Leishmaniasis is one of the major neglected tropical diseases of the world. Druggable targets are the parasites’ cysteine proteases (CPs) of clan CA, family C1 (CAC1). In previous studies we identified two peptidomimetic compounds, the aziridine-2,3-dicarboxylates 13b and 13e, out of a series of inh...
Uloženo v:
| Vydáno: |
2016
|
|---|---|
| Témata: | |
| On-line přístup: | http://hdl.handle.net/10872/13968 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Podobné jednotky: Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.
- Aziridine-2,3-Dicarboxylates, Peptidomimetic Cysteine Protease Inhibitors with Antileishmanial Activity
- Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents
- Intraspecies differences in hemostatic venom activities of the South American rattlesnakes, Crotalus durissus cumanensis, as revealed by a range of protease inhibitors
- Inhibitors of Snake Venoms and Development of New Therapeutics
- Comparison of estradiol, testosterone, vitellogenin and cathepsin profiles among young adult channel catfish (Ictalurus punctatus) females from four selectively bred strains
- Structure-Based Alignment and Comparative Molecular Field Analysis of Acetylcholinesterase Inhibitors